Ascletis' ASC30 obesity drug shows 75-day half-life in US Study
Ascletis announces ultra-long-acting subcutaneous depot maintenance formulation of small molecule GLP-1R agonist ASC30 with 75-Day observed half-life in participants with obesity
Ascletis announces ultra-long-acting subcutaneous depot maintenance formulation of small molecule GLP-1R agonist ASC30 with 75-Day observed half-life in participants with obesity
The survey revealed that the proportion of individuals experiencing constant thoughts about food throughout the day declined by 46 percent after starting Wegovy
Brenntag will supply Food & Nutrition customers in the United States and Canada with Lallemand’s renowned Nutrilife baking enzyme range
Late-breaking data presented at WCLC highlight significant and sustained improvements in overall survival, including more than doubling five-year survival rates compared to chemotherapy alone
Launches National IVD validation portal and protocols; highlights India’s strengthening health research ecosystem
Advent acquired Zentiva from Sanofi in 2018 and transformed the company into a highly successful standalone business
Element5’s Agentic AI platform will be integrated with the HCHB EHR
Philips and Masimo will also collaborate on the development and co-promotion of next-generation monitoring solutions
The FDA is beginning rulemaking to close the “adequate provision” loophole
Cagrilintide represents a novel approach to obesity management
Subscribe To Our Newsletter & Stay Updated